Xenon Pharmaceuticals (XENE) Operating Expenses (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Operating Expenses of $112.3 million for Q1 2026, up 28555.1% year-over-year from N/an in Q1 2025, and up 141.43% quarter-over-quarter from -$271.1 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Operating Expenses (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Operating Expenses for 14 consecutive years, with $112.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 28555.1% year-over-year to $112.3 million; the TTM figure through Mar 2026 stood at -$64.8 million (up 68.45% YoY), while the FY2025 annual figure was -$332000.0, up 89.02% from the prior year.
- Operating Expenses climbed to $112.3 million in Q1 2026 per XENE's latest filing, from -$271.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $112.3 million in Q1 2026 and bottomed at -$271.1 million in Q4 2025.
- Historically, Operating Expenses has averaged $8.3 million across 5 years, with a median of $38.3 million in 2022.
- Annual changes were most pronounced in 2025 — Operating Expenses tumbled 577.55% — and 2026, when it jumped 28555.1%.
- Xenon Pharmaceuticals' Operating Expenses stood at $43.3 million in 2022, then rose by 23.92% to $53.7 million in 2023, then plunged by 481.5% to -$204.8 million in 2024, then slumped by 32.36% to -$271.1 million in 2025, then jumped by 141.43% to $112.3 million in 2026.
- Business Quant data shows XENE's Operating Expenses at $112.3 million in Q1 2026, -$271.1 million in Q4 2025, and $96.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 123.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.16 Mn |
| Mar 31, 2026 | 112.33 Mn |
| Dec 31, 2025 | -271.14 Mn |
| Sep 30, 2025 | 96.34 Mn |
| Jun 30, 2025 | -2.32 Mn |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | -204.85 Mn |
| Sep 30, 2024 | -557,000.00 |
| Jun 30, 2024 | -343,000.00 |
| Mar 31, 2024 | 59.04 Mn |
| Dec 31, 2023 | 53.70 Mn |
| Sep 30, 2023 | 55.68 Mn |
| Jun 30, 2023 | 55.62 Mn |
| Mar 31, 2023 | 49.05 Mn |
| Dec 31, 2022 | 43.33 Mn |
| Sep 30, 2022 | 38.26 Mn |
| Jun 30, 2022 | 30.85 Mn |
| Mar 31, 2022 | 26.14 Mn |
| Dec 31, 2021 | 28.58 Mn |
| Sep 30, 2021 | 23.72 Mn |